Transcript of recent CC:
The importance of relapse was brought up in our discussion of AF drugs. The question from the RBC analyst uncovers the only mention I've noticed to date regarding relapse from rsd1235.
CORPORATE PARTICIPANTS
Don Graham
Cardiome Pharma Corp. - Director, Corporate Communications
Bob Rieder
Cardiome Pharma Corp. - Vice Chairman, CEO
Doug Janzen
Cardiome Pharma Corp. - President, Chief Business Officer
Chuck Fisher
Cardiome Pharma Corp. - Chief Medical Officer
CONFERENCE CALL PARTICIPANTS
Bret Holley
CIBC World Markets - Analyst
David Dean
Sprott Securities - Analyst
Joseph Schwartz
Leerink Swann - Analyst
David Martin
Dundee Securities - Analyst
Brian Bapty
Raymond James - Analyst
Cosme Ordonez
GMP Securities - Analyst
Philippa Flint
RBC Capital Markets - Analyst
PRESENTATION
Operator
Good morning, ladies and gentlemen, thank you for standing by. Welcome to the Cardiome Pharma oral Phase IIa interim results conference call. At this time, all participants are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions will be provided at that time for you to queue up for questions. (OPERATOR INSTRUCTIONS) I would like to remind everyone that this conference call is being recorded on Monday, July 24, 2006, at 6 AM Pacific Time. I will now turn the conference over to Mr. Don Graham, Director of Corporate Communications. Please go ahead, sir.
Don Graham - Cardiome Pharma Corp. - Director, Corporate Communications
Thank you, Melissa. Good morning, everyone. Thank you for calling in to our conference call today to discuss our oral Phase IIa results. As Melissa said, my name is Don Graham, Director of Corporate Communications; and with me today and dialing in is Bob Rieder, Chief Executive Officer of Cardiome.
Bob Rieder - Cardiome Pharma Corp. - Vice Chairman, CEO
Good morning, everyone.
Don Graham - Cardiome Pharma Corp. - Director, Corporate Communications
In our office with me is Doug Janzen, President and Chief Business Officer with Cardiome.
Doug Janzen - Cardiome Pharma Corp. - President, Chief Business Officer
Good morning, everyone.
Don Graham - Cardiome Pharma Corp. - Director, Corporate Communications
And again, dialing in is -- with me is Chuck Fisher, Executive Vice President and Chief Medical Officer.
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
Good morning, everyone.
Don Graham - Cardiome Pharma Corp. - Director, Corporate Communications
Before we proceed, let me first discuss our forward-looking statements disclaimer. Any statements, expectations, and assumptions contained in this presentation that do not describe historical facts and discuss the effects of anticipated drugs or compounds, the successful integration and commercial viability of acquired intellectual property or other assets, the anticipated size of commercial markets for our current and future products, and projected results of our operations constitute forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any forward-looking statements contained in this presentation are based on the Company's current expectations, are not guarantees of future performance, and are subject to a number of risks and uncertainties. Such risks and other risks are identified in our filings with the U.S. Securities and Exchange Commission, including but not limited to those appearing in Exhibit 1.1 under the heading Risk Factors to our annual report on Form 40-F filed with respect to our fiscal year ended December 31, 2005.
Now that the formalities are finished, I would like to pass this conference call over to Mr. Bob Rieder.
Bob Rieder - Cardiome Pharma Corp. - Vice Chairman, CEO
Thank you, Don, and thank you to all of you for joining us on this very auspicious location in Cardiome's history. Up until this point in our development, most of our energy and effort and success has been in the intravenous development of RSD1235. I think the world in general has rightfully taken the viewpoint that because a drug works on the intravenous side, it may not necessarily work on the oral application.
While there is still a very long way to go in this program, we now have some tangible, real evidence of efficacy in relation to the oral applicability of the program.
This is very, very important to us as a Company, quite clearly. It is important both in our ability to now generate value from a second program; and also, and even more importantly, our ability to bring benefit to patients who are sorely in need of a therapy that helps them to safely and effectively stay in normal heart rhythm longer.
We are very, very encouraged by these results, all the more so because they took place at the low-dose end of the spectrum, and really look forward to continuing to develop this new asset within Cardiome as we go forward. So with that as background and preamble, let me now pass the meeting over to Doug Janzen.
Doug Janzen - Cardiome Pharma Corp. - President, Chief Business Officer
Thanks, Bob. I certainly want to share Bob's comments about how excited we are with these results. I want to make clear to those of you on the line this is just an interim analysis. We expect full analysis of both the 300-mg cohort and the 600-mg cohort to occur here later on this quarter.
One of the reasons we are so excited is this analysis that we have reported today is based on the 300-mg cohort against just half of the placebo population. Those of you who understand stats recognize that it has in it a smaller placebo group; certainly could eclipse the effect of the drug. So to see such a clear signal for this interim look has us very excited.
So before we move on to questions here, I just want to publicly acknowledge Dr. Fisher, who is on the phone today, and the entire oral 1235 team at Cardiome. It is hard for us to give credit to our clinical staff when the results work out well; but we can certainly give credit when the execution works out well.
Those of you who read our press release have also noticed that the 600-mg cohort not only has done enrollment but has actually completed dosing, which is almost a quarter ahead of what we were originally expecting. So kudos to Chuck and his whole group. They have been juggling both the RTF and the trial. So thank you very much, Chuck.
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
You're welcome.
Doug Janzen - Cardiome Pharma Corp. - President, Chief Business Officer
I think, at this point, operator, we will open the line to questions
QUESTION AND ANSWER
Operator
(OPERATOR INSTRUCTIONS) Bret Holley from CIBC.
Bret Holley - CIBC World Markets - Analyst
Congratulations on really strong results. A couple of questions. The first really concerns the number of patients that converted in the three-day run-in period on drug versus placebo. Do you have any data for how that looked?
Doug Janzen - Cardiome Pharma Corp. - President, Chief Business Officer
In the interim analysis there was not a stat-sig difference between placebo or drug group as far as successful conversion with this low-dose. We are interested -- we will be certainly looking at that again, when we look at the 600-mg dose.
Bret Holley - CIBC World Markets - Analyst
Can you give us some idea of just the raw number of patients who converted in the run-in period?
Doug Janzen - Cardiome Pharma Corp. - President, Chief Business Officer
Chuck, do you have that?
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
They're about similar in both groups, a little bit towards the placebo. But the numbers are very small, so I would be hesitant to make any statement at this time.
Bret Holley - CIBC World Markets - Analyst
Okay. You didn't give the actual p-value. I just wanted to get an idea on the interim analysis -- again with the proviso we are going to see more complete data at the end of the trial -- how close you really were and what was the statistical hurdle you were shooting for on the interim.
Bob Rieder - Cardiome Pharma Corp. - Vice Chairman, CEO
Let me answer that in the broader scale. This is an exploratory study. It was never sized with statistical significance as our objective. What we wanted to do was make sure that we had -- all of the assumptions that we made based on historical testings in this arena were appropriate and robust. And we wanted to get a preliminary look at safety and efficacy of the drug in the actual patient population. Obviously, we had already dosed it in a Phase I safety study.
So the study was never sized for statistical significance. Chuck, do you have any comments that you would like to make beyond that?
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
I think Bob is correct, Bret. I'm actually very conservative, and I'm very pleased with these results at this point. The key thing which Doug mentioned at the outset is we only have half the placebo group here. When you add that group in -- and remember, the randomization was 2 to 1 for the overall trial -- but the actual final analysis will allow each group to be compared to the placebo group, right? And when you do that I think you will be very pleased.
Bret Holley - CIBC World Markets - Analyst
Okay, that is helpful. I guess the last question and I will get back in the queue. I guess for Chuck, can you put these results in any historical perspective at this point? Is it any kind of ability to kind of compare to amiodarone or propafenone at this point, on what they would have done in a similar patient population with a similar trial (inaudible)?
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
If we look at the DAFNE trial, which is kind of the outlier, they had a very steep placebo curve that most folks have said is not reproducible. We actually have a placebo curve that I think recognizes reality and real-life practice. So that is number one, and with that, we still look very positive.
Number two, we have a safety profile that I think is extremely positive. So without getting into specifics until we have a chance to do final analysis, Bret, I think that you could say this is a sea change.
Bret Holley - CIBC World Markets - Analyst
Great, thanks very much.
Operator
David Dean from Sprott Securities.
David Dean - Sprott Securities - Analyst
Congrats. Two questions. First of all, just around the statistical analysis at the end of the study, obviously you have unblinded half of the placebo group or so. Now, I am wondering if you are able to, using proper statistics, then do an analysis using that whole placebo group at the end.
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
I think, we have kind of -- if you look at just this half this placebo population, we think if we model that second half -- if the second group of placebo performs in a similar way the first half performed, we expect not only we'll exceed stat-sig on this 300-mg cohort -- that is making an assumption. So we are not -- we need to see the data here later on this quarter. But if you assume that both placebo halves perform equally, this 300-mg has been a very clear stat-sig signal.
David Dean - Sprott Securities - Analyst
Okay, so to be clear, though, are you going to put out a p-value at the end of the study?
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
Absolutely, when the final study is completed. At this point we have an incomplete study.
David Dean - Sprott Securities - Analyst
Okay, okay.
Bob Rieder - Cardiome Pharma Corp. - Vice Chairman, CEO
If I can just answer your question a little bit, David. Remember, it is a Phase IIa; so that allows it to be an exploratory analysis. So the type of statistical rules we would apply in a -- that we would submit for a final registration are slightly different.
This gives us an opportunity to get an early look for trend towards signal. At the end the stats will be played out in the classic way, which is why we're hesitant to give a p-value this early.
David Dean - Sprott Securities - Analyst
Sure, okay. I understand that. Now, could you describe maybe some of the nonserious adverse events that might have been noted? Like was there any tasting or anything like that?
Bob Rieder - Cardiome Pharma Corp. - Vice Chairman, CEO
Surprisingly, no. I think our interpretation of that is while we have seen that some with the IV formulation it is because you get a much quicker, really higher peak level; and as you know, they all go away in about 10 or 15 minutes. But none of those types of side effects were observed in this trial at all.
David Dean - Sprott Securities - Analyst
Great. Lastly, any speculation or news on the refiling of the NDA?
Doug Janzen - Cardiome Pharma Corp. - President, Chief Business Officer
I think -- it is perhaps this is a topical time; I know we are going to get other questions on the RTF. We're still -- we have met with the agency; we put out a press release around the Astellas amendment. We still think a Q3 refiling is reasonable.
But we also want to kind of put forward in front of investors that if the clinical teams come back to us and suggest it is going to take slightly longer, we're not going to hesitate to allow that refiling to move into October or November.
We are firmly committed to having the NDA in absolutely the best state possible before we refile. So we are expecting it will be second half of this year. We still think Q3 is reasonable.
But we are overturning every single stone in an attempt to make this NDA successful. Probably the rate-limiting step is going to be having a third party come in and do a QCQA of the whole refiling.
I guess for those of you on the call, just for your abdication, maybe I will have Chuck kind of walk through just what the teams are working on as far as the resubmission project. Chuck?
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
Yes. First off, we have had some very positive and very successful meetings with the FDA, and are having ongoing dialogue with them. I believe that is a very positive relationship, through our partner Astellas and our contribution to that. So we were participants in all of that.
Two, we have broken the whole of the NDA down into a variety of team-related things and are meticulously working our way through every single aspect of it, such that at time of resubmission I think we will more than have addressed any issues or concerns the FDA had.
They actually have evidence back to us that they are very pleased with the responsiveness and are working to help us partner, get it back, and get it in good shape in a timely fashion.
David Dean - Sprott Securities - Analyst
Okay, great. Thanks guys.
Operator
Joseph Schwartz with Leerink Swann.
Joseph Schwartz - Leerink Swann - Analyst
Congratulations on such robust data. I was wondering if -- I saw that the press release mentioned that there was no evidence of Torsades in the study. Any QT prolongation witnessed at all?
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
I don't have all the individual analyses on all the waveforms back yet, because it is a preliminary analysis. So I can't really answer that one right now. But there are no events that in any way suggested that that was the case.
Joseph Schwartz - Leerink Swann - Analyst
Great. It numerically looked well tolerated versus placebo. I was wondering if you could discuss were there any trends towards any particular adverse events for the drug?
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
Actually, it was quite balanced with the exception of there was some degree of bradycardia observed in the treatment group versus the placebo. They were all asymptomatic, but a slightly larger number. Otherwise, there is basically a balance between both groups.
Joseph Schwartz - Leerink Swann - Analyst
Okay, great. As far as long-term exposure goes, is there any opportunity for any of the 300 or 600-mg patients to continue on the drug?
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
Not in this particular trial. Because again, it is a preliminary trial. Once we have the full data set we would have to go back and have conversations with regulators. So as supposed to were we to have a trial towards registration and then a registry following it, that might be a possibility for the future. But at this point, we are limited.
We have done the tox, etc., so that we can go forward with a longer trial. But we would need to file that pending results of filing these results first.
Joseph Schwartz - Leerink Swann - Analyst
Great. Just a couple more. About, in terms of the interaction of the RSD1235 with any other drugs that are used in this setting, what do we know about how that might look?
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
The groups are extremely balanced on essentially all the drugs that you might expect in this particular population. So we're very pleased to see that it represents real-life care.
In terms of the drug direction studies, we are actually in the midst of conducting those as we speak right, now which will be more specific to understanding any metabolic pathways or drug interaction related issues.
Doug Janzen - Cardiome Pharma Corp. - President, Chief Business Officer
Just to add a little bit to Chuck's comments, Joe, in this study on baseline [concomitant] meds, when half the patients were on ACE and ARBs, well over 90% were on antithrombotics; a small number was on antihypertensives; about 75% were on beta blockers.
We also had patients on calcium channel blockers, dig, diuretics, diabetic meds. So that this was a real-world setting, and we're excited to see that 1235 while we are at 28 days of dosing in those patients that stayed in normal rhythm, it wasn't interacting in a negative way with these other agents.
Joseph Schwartz - Leerink Swann - Analyst
That is positive. In terms of the actual plasma concentration of the drug, relative to response in each of these subpopulations, when can we expect to see some of that data?
Doug Janzen - Cardiome Pharma Corp. - President, Chief Business Officer
On the final analysis, we don't have the PKPD data from this interim cohort at this point. So that will be later on in the second half of this year.
Joseph Schwartz - Leerink Swann - Analyst
Great, thanks very much.
Operator
David Martin from Dundee Securities.
David Martin - Dundee Securities - Analyst
Congratulations on the results. A couple of questions. In the DAFNE study, which you reference, the lowest dose was actually the most effective. I am wondering if you have any insight? Is that an oddity that you don't expect to occur here? Do you expect the 600 to be more efficacious? Why might dronedarone have shown best efficacy at the lower dose?
Second question, in this low-dose arm versus the half of the placebo, do you know what the median and mean times in AF were prior to coming into the trial? Were they well balanced?
The last question is on the 600-mg arm. Are you seeing safety events at this point? If you are, is everything the same as the 300, or are you seeing any differences?
Doug Janzen - Cardiome Pharma Corp. - President, Chief Business Officer
I will answer the first one and leave Chuck to the second two questions. I think Sanofi themselves can't explain that bell-shaped dose-response curve for dronedarone. Certainly Cardiome can't explain it. It is not our product. Sanofi hasn't been able to explain why their low dose had a better effect on efficacy than the two higher doses.
We have no reason whatsoever to assume the same off of 1235. That is why we're running the second cohort. I will leave the next two questions for Dr. Fisher.
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
David, the groups were extremely well balanced. I have run lots and lots of trials, and this is one of the most balanced trials I have ever seen.
Viz. your question on the 600 milligrams of safety, we have -- obviously, we get blinded reviews or assays or things like that, and there has been no particular signal at all in the overall trial. So at present I don't have any reason to say that the 600 would be any different than the 300.
David Martin - Dundee Securities - Analyst
Okay, great. Thanks.
Operator
Brian Bapty from Raymond James.
Brian Bapty - Raymond James - Analyst
Nice data. Just a quick question; actually a couple of questions. First of all, just looking at the [StataCorp] data, your placebo numbers and your low-dose number look literally identical to their placebo number and their high-dose number. Just a few could maybe frame your 600-milligram dose into what you expect to hit in terms of maximum plasma levels versus with IV; and just maybe if we can make some forecasting as to whether or not this efficacy will actually continue to increase.
And two, if you could frame up just where you are in terms of timelines with your Phase IIb study. And a little forward-looking beyond that, where you think a Phase III would start to initiate and how long that whole process would take.
Doug Janzen - Cardiome Pharma Corp. - President, Chief Business Officer
Sure, Brian; thanks for the question. We will split those up again. I think regarding your PK question, we have not yet seen PK data from all 1235 in sick patients. So our exposure to date in patients (inaudible) healthy volunteers, Phase I study.
So we assume that the 600-mg gets us somewhere in the level approaching 40% to 50% at peal levels of what we see in the IV conversion dose. But what we see in patients is a compete -- it's a guess at this point.
So as far as kind of modeling or predicting what that is going to do in efficacy on the second cohort, we just don't have data to make those type of guesses. We're thinking of having more of 1235 onboard (inaudible) produce better results than having less. But beyond that, we have no data to point to.
Chuck, do you maybe want to talk about on the Phase IIb study or other plants for a Phase II/III?
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
Sure. Well, first off, Brian, we're just extremely pleased to get a signal this early in this part of the development program. So one of the things we want to do is carefully look at the whole of the data set when are completed with the 300 and the 600, to make sure we fully understand it.
But at present, I think our guidance would be we are on track as what we have previously said before, to be moving forward.
But the best way to answer that question is let's get the full data set, because it may influence the possibility of would we do a -- to answer your last question -- could there be a possibility for Phase II/III? That possibility exists; but I think it is way premature to speak to that part of the program.
Brian Bapty - Raymond James - Analyst
Okay. Just on that basis, if you were to go into a II/III, if all the stars lined up perfectly, what would the patient population in terms of size be, do you think? How long would you say that process would take? Again, making the assumption you would in fact go into a II/III.
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
Well, obviously before I got into that, I'd want to make sure that I had had my end of Phase II meeting with the agency and had a commitment from them. So I would be hesitant to make that commitment here, absent seeing the rest of the data and having a follow-up discussion with them.
Doug Janzen - Cardiome Pharma Corp. - President, Chief Business Officer
When you look at Sanofi's original package for dronedarone, we saw roughly 1,500 patients exposed to the drug. The longest duration of a study of -- just a bit under 18 months.
Now that was the Sanofi filing; so it is hard to know if 1235 will have a similar profile also. It seems, at least according to most people's analysis, that Sanofi received an approvable letter; and they have committed to other clinical work around that. So we don't really have any FDA goalposts as to how we design a Phase III program.
One thing we are very excited about, though, going back to your question, this current population is not a representative population of where we think clinical practice will see 1235 oral being used. This group had a high degree of a-fib burden entering the study. Most of them had -- actually all of them had had a median time of a-fib on the drug group over 60 days.
So to see such a strong signal from the drug in a patient population that we think is fairly compromised is one of the reasons why we are so excited. It's one of the reasons why we think going forward in a more representative population that 1235 will continue to deliver.
Brian Bapty - Raymond James - Analyst
Just out of curiosity then, if you were to get into a II/III type program, that would likely be something you would do in combination or partnership with a large pharma. It would seem like a fairly big undertaking. On that note, just in a business development perspective, where do you think, Doug, you would look to potentially maybe saddle up to a partner here? Or would you in fact potentially start this study on your own and enlist a partner thereafter?
Doug Janzen - Cardiome Pharma Corp. - President, Chief Business Officer
We're not committing to partnering 1235 oral at this point. We think we have one of the more exciting products in the cardiovascular realm that we are de-risking in the clinic as we speak. The need to bring a partner to the table is not there at the current time. We would rather continue to drive excitement amongst the pharma space, as opposed to marry one of them regarding this asset at this point.
Brian Bapty - Raymond James - Analyst
Thanks, guys, again. Good data. Have a good day.
Operator
Cosme Ordonez from GMP Securities.
Cosme Ordonez - GMP Securities - Analyst
Congratulations again, very robust results. Just a couple of questions. With regard to the patient demographics of the study, could you add some more color about what was the average age; also, how many of these patients have underlying diseases; and if there were a particular type of disease that was more prevalent in both placebo and the treated group?
With regard to the higher-dose cohort, you mentioned that you have completed enrollment. So we are assuming that you already have some safety data that is available. So if you could please comment on these, that would be very helpful.
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
Sure. Regarding the completed enrollment, we have just recently completed accrual of patients in the higher-dose group. As I mentioned earlier on the call, we saw no change in signal in the latter half of the trial or accrual when the higher-dose patients were put in. So at this point in time we have no reason to believe it is different than what we have reported out there.
In terms of your earlier question, about roughly half the patients in each group are greater than 65 years of age, so that would be consistent with what one would expect in this population. The underlying disease states are really quite well balanced in a variety of things, including heart failure, etc. So I think it is a fairly representative population. As for instance, 80% of them in either group have cardiovascular disease. The normal mixture of the kinds of things you would expect.
Cosme Ordonez - GMP Securities - Analyst
Thank you.
Don Graham - Cardiome Pharma Corp. - Director, Corporate Communications
I think, operator, we will take one more question. I know the market is about to open, so let's make this our last question.
Operator
Philippa Flint from RBC Capital Markets.
Philippa Flint - RBC Capital Markets - Analyst
Can you comment on the median time to relapse in each of the placebo and the RSD group?
Bob Rieder - Cardiome Pharma Corp. - Vice Chairman, CEO
For Chuck?
Chuck Fisher - Cardiome Pharma Corp. - Chief Medical Officer
Yes, I'm just wanting to find that for a second.
Bob Rieder - Cardiome Pharma Corp. - Vice Chairman, CEO
In general, the patients in both populations who relapsed tended to relapse in the first kind of 10 days after they were cardioverted. After that, the relapse rate dropped off fairly sharply.
So if you thought about seven or eight days being the median time in the placebo group, and probably 10, 11 days in the drug group, I think you would be pretty close to where we got to.
Philippa Flint - RBC Capital Markets - Analyst
Correct me if I am wrong, but did you not design this around showing a 50% hazard ratio as one of the primary endpoints? I recognize it is an exploratory study, but is that what you are looking for at the end when you to (multiple speakers) final?
Bob Rieder - Cardiome Pharma Corp. - Vice Chairman, CEO
No, we were not looking for any particular hurdle on the efficacy side. Indeed, when we picked this dose, we picked a dose that we thought would have some possibility of showing an efficacy signal; but we certainly did not expect a robust signal from this dose in the study.
So we had no preset hurdles on efficacy. Again, that would have been really quite a foolish thing to do in a study that was this small in size. If you look at the historical data around similar types of studies with similar drugs, you would see this is on the small side.
What we wanted to do was explore, make sure we had the popular patient population right, make sure we got some sort of signal around safety and efficacy. And we are clearly very pleased with these results.
Philippa Flint - RBC Capital Markets - Analyst
So when you report on the final analysis and you do have some statistical results, what efficacy parameters will you mainly be looking at?
Bob Rieder - Cardiome Pharma Corp. - Vice Chairman, CEO
The statistical analysis at the end of this study will be based on quantifying the separation between 2 Kaplan-Meier survival in normal heart rhythm curves. So there is a special kind of analysis that takes into account the time course of separation at the two Kaplan-Meier curves, as well as the ending separation between the two curves. That is the statistical analysis that is appropriate for these two patient populations. That is the one that we will be of reporting on.
Philippa Flint - RBC Capital Markets - Analyst
And that is -- the Kaplan-Meier survival is based on time to relapse?
Bob Rieder - Cardiome Pharma Corp. - Vice Chairman, CEO
It encompasses both time to relapse and total number of relapses.
Philippa Flint - RBC Capital Markets - Analyst
I see, okay. That is great. Thank you very much.
Don Graham - Cardiome Pharma Corp. - Director, Corporate Communications
I think at this point with the market opening we will end the call. So thank you, operator. Any of those of you are still in the queue, feel free to contact us directly and we hopefully can answer your questions.
Bob Rieder - Cardiome Pharma Corp. - Vice Chairman, CEO
Thanks for being with us today, gentlemen. Ladies and gentlemen.
Operator
Ladies and gentlemen, this concludes the conference call for today. Thanks for participating. You may now disconnect your lines. |
